We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*

Monoclonal antibodies have received significant attention over the past month and we previously podcasted on antibodies that target SARS-CoV-2. In this episode, we review several recent studies on a different "mab", tocilizumab,  which targets inflammation mediated by interleukin-6 that is overly ramped up. 

We review:

Stone et al  ( RCT)

Hermine et al (RCT)

Salvarani et al. (RCT)

STOP-COVID (observational)

Show notes (references/graphics): FOAMcast.org

Thanks for listening,
Lauren Westafer and Jeremy Faust

We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*

Monoclonal antibodies have received significant attention over the past couple of weeks. In this episode, we review what we know, as of October 9, 2020, about monoclonal antibodies as a therapy for COVID-19. 

Show notes (references/graphics): FOAMcast.org

Thanks for listening,
Lauren Westafer and Jeremy Faust

We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*

We review a retrospective evaluation of COVID-19 infections in employees after a protocol that increased the use of high flow nasal cannula (Westafer et al)

Show notes (references/graphics): FOAMcast.org

Thanks for listening,
Lauren Westafer and Jeremy Faust